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Abstract
Background: Increased activation and increased survival of T lymphocytes characterise bronchial asthma.
Objectives: In this study the effect of budesonide on T cell survival, on inducible co-stimulator T cells (ICOS), on Foxp3 and
on IL-10 molecules in T lymphocyte sub-populations was assessed.
Methods: Cell survival (by annexin V binding) and ICOS in total lymphocytes, in CD4+/CD25+ and in CD4+/CD25- and Foxp3
and IL-10 in CD4+/CD25+ and in CD4+/CD25-cells was evaluated, by cytofluorimetric analysis, in mild intermittent
asthmatics (n = 19) and in controls (n = 15). Allergen induced T lymphocyte proliferation and the in vivo effects of
budesonide in mild persistent asthmatics (n = 6) were also explored.
Results: Foxp3 was reduced in CD4+/CD25- and in CD4+/CD25+ cells and ICOS was reduced in CD4+/CD25+ cells but it was
increased in CD4+CD25-in asthmatics when compared to controls. In asthmatics, in vitro, budesonide was able to: 1)
increase annexin V binding and to reduce ICOS in total lymphocytes; 2) increase annexin V binding and Foxp3 and to reduce
ICOS in CD4+/CD25- cells; 3) reduce annexin V binding and to increase IL-10 and ICOS in CD4+/CD25+ cells; 4) reduce cell
allergen induced proliferation. In vivo, budesonide increased ICOS in CD4+/CD25+ while it increased Foxp3 and IL-10 in
CD4+/CD25+ and in CD4+/CD25- cells.
Conclusions: Budesonide modulates T cell survival, ICOS, Foxp3 and IL-10 molecules differently in T lymphocyte sub-
populations. The findings provided shed light on new mechanisms by which corticosteroids, drugs widely used for the
clinical management of bronchial asthma, control T lymphocyte activation.
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Introduction
Asthma is a heterogeneous disorder that is characterized by
variable and largely reversible airflow obstruction, airway inflam-
mation and hyperresponsiveness. Airway inflammation in allergic
asthma is characterized by exaggerated activation of T helper
type-2 (Th2) cells, IgE production and eosinophilia [1]. An
increased survival of immune effector cells (eosinophils, macro-
phages and T lymphocytes) within the airways contributes to the
severity of asthma [2]. T-lymphocytes play a crucial role in the
development of airway inflammation. Activation, differentiation
and effector cell function of T-helper cells (Th) are directed by co-
stimulatory molecules which deliver critical signals modulating the
antigen-specific signal of the T-cell receptor (TCR). Inducible co-
stimulatory antigen (ICOS) is one of the most intensively studied
co-stimulatory molecules [3]. Emerging evidences in animal
models demonstrate a relevant role of ICOS in asthma. Blockade
of ICOS in sensitised mice significantly reduced signs of allergic
airway inflammation, such as increased IgE and Th2 cytokine
production [3] and ICOS-positive regulatory T cells (Tregs)
suppress IL-17 production and thereby reverse established, IL-17-
dependent airway hyper-reactivity in mice [4]. Tregs exert an
important role in the control of T-cell-mediated inflammation in
asthma [5] [6]. Two major subsets of Tregs are identified: CD25+
forhead box P3 (Foxp3)+ Tregs and IL-10-producing Tregs. The
numbers or function of both Treg subsets are deficient in patients
with atopic allergic diseases including asthma [7].
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Corticosteroids are the most effective anti-inflammatory agents
and topical corticosteroids including budesonide are the recom-
mended therapy in current guidelines for asthma [8]. Corticoste-
roids act on Tregs, increasing IL-10 production [9] and enhancing
IL-10 Treg function [7]. Corticosteroids inhibit T-cell activation
and production of Th2 cytokines [10] [11] and increase T cell
apoptosis [12] [13].
The objectives of this study were to assess the effects of
budesonide (BUD), a potent inhaled corticosteroid, in cell survival
and in the expression of ICOS, IL-10 and of Foxp3 in
CD4+CD25+ and CD4+CD25- peripheral T lymphocytes
obtained from asthmatic patients in comparison to control
subjects.
Materials and Methods
Subjects and study design
The study was approached by in vitro and in vivo assessments of
BUD effects in asthma. For the in vitro evaluations, we selected 19
atopic patients with mild intermittent asthma, according to the
criteria of the American Thoracic Society [14], and 15 control
subjects without allergic diseases or asthma (Table 1). All asthmatic
patients (Table 1) were characterized by a reversible airway
obstruction assessed by an increase of $12% of forced expiratory
volume in one second (FEV1) after inhalation of 200 mg of
salbutamol. The asthma diagnosis and the assessment of its
severity were performed according to the Global Initiative for
Asthma [15]. All recruited subjects were never-smokers. Atopy was
established by aeroallergen skin prick test (Alk Abello`, Hørsholm,
Denmark). None of the patients recruited for evaluating the in vitro
effects of BUD received any corticosteroid treatment. For assessing
in vivo effects of BUD, eight atopic steroid naı¨ve patients with mild
persistent asthma (Table 1) and uncontrolled disease as assessed by
Asthma Control Test (ACT)) (score #19) were evaluated before
and after 12 weeks of inhaled BUD treatment (twice daily
treatment with 200 mg BUD). Pulmonary functional tests (Polgar
reference values) and clinical assessment (morning and evening
peak expiratory flow (PEF) and ACT were performed before and
after BUD treatment. Subjects who had bronchial or respiratory
tract infections during the month before the test were not included.
The study fulfilled the criteria of the Ethics Committee of
Policlinico-Giaccone Hospital-Palermo, was approved and was in
agreement with Helsinki Declaration. All subjects had given their
written informed consent.
Peripheral blood mononuclear cells (PBMC) cultures
Peripheral blood mononuclear cells (PBMC) were isolated from
blood samples (10 ml) of asthmatic patients (mild intermittent and
persistent) and of controls by Ficoll-Hypaque (Pharmacia) gradient
centrifugation. The cells were suspended in RPMI 1640 tissue
culture medium (Invitrogen Life Technologies) supplemented with
1% heat-inactivated FCS (Invitrogen Life Technologies), 2 mM L-
glutamine, 20 mM HEPES, 100 U/ml penicillin, 100 mg/ml
streptomycin, 561025 M 2-ME and 85 mg/ml gentamicin. Purity
and viability were tested using trypan blue exclusion.
For assessing in vitro effects of BUD, the cells (26106 cells/ml)
were stimulated within tubes (Becton Dickinson, Mountain View,
CA) for 24 hours in the absence and in the presence of BUD
(Italchimici, Italy) (1028 M final concentration). The concentra-
tion range of BUD and incubation times were selected in
preliminary experiments (figure S1). Initially, three concentrations
of BUD (1027, 1028 and 1029 M) and two time points (24 and
48 hrs) in cell apoptosis preliminary experiments in total
lymphocytes were tested. Since 1027 and 1028 M were similar
in their effects and were more potent than 1029 M and since the
higher effect was observed at 24 hours, the concentration of
1028 M and the time point 24 hours were selected (see figure S1).
In some experiments, the cells (26106 cells/ml) were cultured
with/without BUD (1028 M for 24 hours) and then stimulated
with the allergen to which the patient was more responsive (for
additional 72 hours).
Table 1. Demographic and clinical characteristics of the study population.
Controls = 15
Mild intermittent
asthmatics =19
Mild persistent
asthmatics = 8 P value
Caucasic race 15 19 8
Gender (M/F) 8/7 8/11 4/4 n.s.
Age (years) 50 (25–75) Percentiles 38 (26–45) 27 (19–37) 32.5 (27.5–36.5) n.s.
FEV1 % of predicted Percentiles 112 (108–119) 99 (93–108) 90.5 (85.5–95.5) n.s.
FEV1 (PRE), L Percentiles 3.8 (2.97–4.07) 3.40 (2.9–3.9) 3.45 (3.05–4.2) n.s
FEV1 (POST), L Percentiles - 3.76 (3.25–4.34) 4.12 (3.44–4.74) n.s.
Bronchodilation test- Reversibility (%)
Percentiles
- 15 (13–16) 15 (13.5–15.5) n.s.
Parietaria judaica+ - 7/19 3/8
Olea+ - 4/19 2/8
Cat+ - 3/19 1/8
Dermatophagoides Pteronyssinus+ - 8/19 4/8
Dermatophagoides Farinae + - 8/19 4/8
CD4+ cells (%) 44.364 50.566* 51.764.5* ,0.05
CD4+/CD25+ cells (%) 3.560.7 4.461.6 561.9 n.s.
CD4/CD25- cells (%) 40.864 4666* 46.463.6* ,0.05
*Mann Whitney versus controls.
doi:10.1371/journal.pone.0048816.t001
Immunoregulatory Effects of Budesonide
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Flow-cytometry
For flow cytometry, analyses were performed on a Becton
Dickinson FACSCalibur System. Lymphocytes were gated by
forward and side scatter and negative controls were performed
using an isotype control antibody (BD PharMingen) (Figure 1).
The analysis, in total lymphocyte gate (R1) was performed on
10,000 events for each sample using CellQuest acquisition and
data analysis software (Becton Dickinson).
Annexin V binding
T cell survival was determined [13] by Annexin V staining in
PBMC previously stained with FITC anti-human CD4 and PE-
Cy5 anti-human CD25 (BD PharMingen).
PE Annexin V staining was performed using a commercial kit
(Bender MedSystem, Vienna, Austria) following the manufactur-
er’s directions. PBMC were analyzed by flow cytometry within
1 hour.
Expression of surface markers
PBMC were stained with PE anti-human ICOS, with FITC
anti-human CD4 and PE-Cy5 anti-human CD25 [all monoclonal
antibodies (mAb) were from BD PharMingen].
Foxp3 intracellular staining
PBMC were stained with PE anti-human CD4 and PE-Cy5
anti-human CD25 (BD PharMingen). Cells were fixed and
permeabilized using the BD PharMingen human Foxp3 Buffer
Set, following the manufacturer’s recommended assay procedure.
Finally, the cells were stained with FITC anti-human Foxp3.
Intracellular cytokine staining
For the detection of intracellular cytokine IL-10, PBMC were
cultured overnight with GolgiStop (2 mM final concentration) (BD
PharMingen). The cells were stained with CD4 FITC and CD25
PE-Cy5 in PBS containing 1% FCS and 0.1% Na azide for
30 min at 4uC. Cells, washed twice in PBS with 1% FCS, were
Figure 1. Gating strategy and isotype controls for flow cytometric identification of lymphocyte subpopulations. PBMC from controls
(n = 15) and from mild intermittent asthmatics (n = 19) were cultured with/without BUD and assessed for further analyses. The total lymphocytes were
gated by forward and side scatter (red coloured R1) and the CD4+CD252 and the CD4CD25+ cells were gated as R 3 and R2, respectively as shown in
A. Histograms for isotype controls for CD4, CD25, ICOS, IL-10 and Foxp3 staining and negative control for annexin V binding (unstained cells) in total
lymphocyte population are shown in B.
doi:10.1371/journal.pone.0048816.g001
Immunoregulatory Effects of Budesonide
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fixed with PBS containing 4% paraformaldehyde for 20 min at
room temperature. After two washes in permeabilization buffer
(PBS containing 1% FCS, 0.3% saponin, and 0.1% Na azide) for
15 min at 4uC, the cells were stained with 0.25 mg of PE anti-
human IL-10 antibody (BD PharMingen). After two more washes
in PBS containing 1% FCS, the cells were analyzed by
FACSCalibur.
Isolation of CD4+CD25+CD127dim Regulatory T cells
CD4+CD25+CD127dim T cells were isolated using magnetic
cell sorting (MACS separation columns, Miltenyi Biotec, Ger-
many) kit following the manufacturer’s directions as previously
described [16].The purified T cells were cultured with or without
BUD and then assessed for IL-10 expression by flow cytometry.
Figure 2. BUD modulates in vitro the annexin V binding of peripheral blood T-lymphocytes. PBMC from controls (n = 15) and from mild
intermittent asthmatics (n = 19) were cultured with/without BUD and were assessed for annexin V binding in total lymphocytes (A), in CD4+CD252
(B) and in CD4+CD25+ cells (C). Individual results, median and 25–75 percentiles are shown. *p,0.05 baseline vs BUD. Arrows indicate the
representative dot plots.
doi:10.1371/journal.pone.0048816.g002
Immunoregulatory Effects of Budesonide
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Cell proliferation assay
PBMC were isolated from asthmatic patients (n = 6) and cell
proliferation was measured using carboxyfluorescein succinimidyl
ester (CFSE) labeling assay. CFSE is used to fluorescently label live
cells and is equally partitioned to daughter cells during division
[16], [17]. Briefly, the cells were incubated with CFSE (Molecular
Probes, Inc. Eugene, OR) (at a final concentration of 5 mM) at
37uC for 10 min. Labeling was blocked by the addition of an equal
volume of heat inactivated FCS. Tubes were placed in ice for
5 min and then washed. After centrifugation, the cells, seeded in
24 well plates (16106 cells/well) in complete RPMI, were
stimulated for 24 hours with and without BUD (1028 M final
concentration) and then incubated with allergen for 72 hours
(37uC- 5% CO2). Cell proliferation was assessed by flow-
cytometry.
Figure 3. BUD affects in vitro the expression of ICOS on peripheral blood T-lymphocytes. PBMC from controls (n = 15) and from mild
intermittent asthmatics (n = 19) were cultured with/without BUD and were assessed for ICOS expression by flow-cytometry in total lymphocytes (A),
in CD4+CD252 cells (B) and in CD4+CD25+ (C) cells from controls (n = 15) and from asthmatics (n = 19). Individual results, median and 25–75
percentiles are shown.*p,0.05 baseline vs BUD.**p,0.05 asthmatics vs controls. Arrows indicate the representative dot plots.
doi:10.1371/journal.pone.0048816.g003
Immunoregulatory Effects of Budesonide
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Statistical analysis
Data are expressed as medians and 25–75 percentiles. All the
statistical analyses were performed using the StatView 5.0.1
software. A non-parametric Mann Whitney test for comparisons
between the two recruited groups was applied. Statistical analysis
of the in vitro and in vivo effects of BUD was performed by Wilcoxon
test P,0.05 was accepted as statistically significant.
Results
Demographic characteristics of the subjects
The demographic characteristics, the clinical and functional
evaluations and the percentages of peripheral CD4+, CD4+/
CD25+ and CD4+/CD252 cells of the studied patients are shown
in Table 1. Significantly higher percentages of CD4+ and of
CD4+/CD252 cells were observed in both mild intermittent and
persistent asthmatics in comparison to controls. No differences
were observed between mild intermittent and mild persistent
asthmatics.
In vitro effects of BUD: Annexin V binding in peripheral
blood T-lymphocytes
Corticosteroids inhibit T-cell activation and production of Th2
cytokines [10] [11] and increase T cell apoptosis [12] [13]. We
initially approached the study assessing in vitro the effects of BUD
in the apoptosis (annexin V binding) of total lymphocytes, of
CD4+/CD25+ and of CD4+/CD25- cells.
The ability of BUD to increase annexin V binding was assessed
in total lymphocytes, in CD4+/CD25+ and in CD4+/CD25- cells.
The total lymphocytes, CD4+CD25+ and the CD4CD25- cells
were gated as shown in figure 1A–B. No significant differences in
the annexin V binding between asthmatics and normal subjects
were detected in total lymphocytes or in CD4+/CD25+ and in
CD4+/CD252 cells (figure 2 A, B, C). BUD significantly
increased the annexin V binding in total lymphocytes (figure 2
A) and in CD4+/CD252 cells (figure 2 B) while it decreased the
annexin V binding in CD4+/CD25+ cells in asthmatic patients
but not in controls (figure 2 C).
Expression of ICOS on peripheral blood T-lymphocytes
sub-populations
ICOS is a co-stimulatory molecule acting as an important
regulator of Th2 lymphocyte function [18]. The effect of BUD in
modulating ICOS expression was assessed in total lymphocytes
(figure 3 A), in CD4+/CD25+ (figure 3 B) and in CD4+/CD252
cells (figure 3 C). The percentage of ICOS positive cells was
significantly reduced in CD4+/CD25+ cells while it was signifi-
cantly increased in CD4+/CD252 cells in asthmatics when
compared to controls. BUD reduced the percentage of ICOS
positive total lymphocytes in asthmatics but not in controls (figure 3
A). In asthmatic patients, BUD significantly reduced the percent-
age of ICOS positive cells in CD4+/CD252 cells (figure 3 B)
while it increased the percentage of ICOS positive cells in CD4+/
CD25+ cells (figure 3 C).
Expression of Foxp3 in peripheral blood T-lymphocyte
sub-populations
In asthmatics decreased T regulatory activities are observed [7].
The effect of BUD in modulating Foxp3+ expression, a
transcription factor characterizing Tregs, was assessed in CD4+/
CD25+ and in CD4+/CD252 cells from asthmatics and from
controls. A reduced percentage of Foxp3 positive cells was
observed in both CD4+/CD25+ and in CD4+/CD252 cells
Figure 4. BUD affects in vitro the expression of Foxp3 in
CD4+CD25+ and CD4+CD25- peripheral blood T-lymphocytes.
PBMC were isolated from controls (n = 15) and from mild intermittent
asthmatics (n = 19), were cultured with/without BUD and were assessed
for Foxp3 by flow-cytometry in CD4+CD252 (A) and in CD4+CD25+
cells (B). Individual results, median and 25–75 percentiles are
shown.*p,0.05 baseline vs BUD.**p,0.05 asthmatics vs controls.
Arrows indicate the representative dot plots.
doi:10.1371/journal.pone.0048816.g004
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from asthmatics when compared to controls and BUD was able to
significantly increase the percentage of Foxp3 positive cells in
CD4+/CD252 but not in CD4+/CD25+ cells in asthmatics
(figure 4 A–B).
Expression of IL-10 in peripheral blood T-lymphocytes
sub-populations
Corticosteroids act on Tregs increasing IL-10 production [9].
The effect of BUD in the expression of IL-10 was assessed in
CD4+/CD252 cells (figure 5 A) and in CD4+/CD25+ cells
(figure 5 B) from asthmatic patients and from controls. BUD was
able to increase the percentage of IL-10 positive cells in CD4+/
CD25+ cells (figure 5 B) but not in CD4+CD252 cells (figure 5 A).
The effect of BUD in IL-10 expression was also assessed in
CD4+CD25+CD127dim T cells to establish whether the observed
effects of BUD are related to Treg or to activated effector T cells
that can transiently express Foxp3. As shown in figure 4C, BUD
was able to increase the expression of IL-10 in
CD4+CD25+CD127dim T cells.
Proliferation of peripheral blood T-lymphocytes
We tested whether BUD affected the proliferation of T
lymphocytes upon allergen exposure. When peripheral T
Figure 5. BUD affects in vitro the expression of IL-10 in CD4+CD25+. PBMC were isolated from controls (n = 15) and from mild intermittent
asthmatics (n = 19), were cultured with/without BUD and were assessed for IL-10 expression by flow-cytometry in CD4+CD252 (A) and in
CD4+CD25+ cells (B). Individual results, median and 25275 percentiles are shown.*p,0.05 baseline vs BUD. C. The expression of IL-10 was also
assessed in CD4+CD25+CD127 dim T cells (see materials and methods for details). Representative dot plot of cells from a patient with asthma at
baseline and following in vitro BUD exposure is shown.
doi:10.1371/journal.pone.0048816.g005
Immunoregulatory Effects of Budesonide
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lymphocytes were stimulated with allergen a significantly increased
cell proliferation was observed. BUD significantly reduced T
lymphocyte proliferation counteracting the effects of the allergen
(figure 6).
In vivo effects of BUD
Finally, the in vivo effects of BUD were tested in mild persistent
asthmatics. BUD was able to increase the percentage of ICOS
positive cells in CD4+/CD25+ cells while it decreased the
percentage of ICOS positive cells in CD4+/CD252 cells
(Figure 7 A–B). Moreover, BUD was able to increase in
CD4+CD25+ and in CD4CD252 cells the percentages of Foxp3
(Figure 7 C–D) and IL-10 (Figure 8 A–B) positive cells. After BUD
treatment, these immunomodulatory effects paralleled the patient
clinical benefits including an improvement of peak flow (Morning
PEF (L min21) baseline = 382640; BUD = 441638; p,0.02.
Evening PEF (L min21) baseline = 421650; BUD = 460645;
p,0.02), improvements in the basal FEV1 (median increase of
15%), no use of rescue medications, improvement of ACT
symptom score (baseline = 15.862.2, BUD = 20.761.6; p,0.02).
Discussion
The present study demonstrates that BUD, an inhaled
corticosteroid widely used for the management of bronchial
asthma, controls asthma inflammation modulating ICOS, cell
survival, Foxp3 and IL-10 expression differently in CD4+/
CD252 and in CD4+/CD25+ cells in peripheral blood. These
mechanisms of action of BUD were demonstrated by an in vitro
and an in vivo approach and provide further understanding on new
mechanisms by which corticosteroids control T lymphocyte
activation. T-lymphocytes play a crucial role in the development
of airway inflammation. Th2 induce and Treg cells suppress
several features of allergic inflammation in asthmatics. One of the
mechanisms leading to the persistence of T- cell activation in
asthma may be related to a reduced T cell survival [19]. T-
lymphocytes represent an important target of anti-inflammatory
drugs, and particularly of corticosteroids. One of the mechanisms
mediated by corticosteroids in target cells is the induction of cell
apoptosis [20], a phenomenon that can be assessed by the annexin
V binding method. Up to now it is unclear whether the
preferential activation of cell apoptosis in specific T lymphocyte
subpopulations may explain the therapeutic activities of cortico-
steroids in asthmatic patients. Only a single Japanese study by
Oneda [21] demonstrates that in asthma dexamethasone induces
cell apoptosis preferentially in T activated effector cells but no
study has explored the effect of BUD in cell survival simulta-
neously in total lymphocytes, CD4+/CD25+ and CD4+/CD252
cells from asthmatics. In the present study CD4+/CD25+ and
CD+/CD252 were not purified to avoid non specific activation
and to assess the BUD effects in a microenvironment where, as in
vivo, mixed populations of immunocompetent cells (including
accessory cells) are present.
Figure 6. Effects of BUD in peripheral T cell proliferation. For cell proliferation experiments, PBMC were isolated from mild intermittent
asthmatics (n = 4), cultured with and without BUD for 24 hours and then stimulated for 72 hours with the most relevant allergen for each patient. Cell
proliferation was assessed using CFSE and analysed by means of flow-cytometry. The analysis were performed on lymphocytes gated by forward and
side scatter. Data are expressed as % of cells with low CFSE expression (A). * p,0.05 (paired t test). Histograms from one representative experiment is
shown (B).
doi:10.1371/journal.pone.0048816.g006
Immunoregulatory Effects of Budesonide
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Here, it is demonstrated that asthmatic patients showed
increased percentages of CD4+ and CD4+/CD252 cells and
that BUD significantly increased the percentage of annexin V
positive cells in total lymphocytes as well as in CD4+/CD252cells.
Differently, BUD decreases the percentage of annexin V positive
cells in CD4+/CD25+ cells in asthmatic patients. In this regard it
also been demonstrated that a low dose of IL-2 can protect
CD4+CD25+ but not CD4+CD252 cells from dexamethasone-
induced apoptosis by affecting forkhead box O3a phosphorylation
through the Akt and serum and glucocorticoid-induced protein
kinase pathways [22].This latter phenomenon may be also due to
the fact that Foxp3 highly expressed on a portion of CD4+/
Figure 7. In vivo effects of BUD in ICOS and Foxp3 expression in peripheral blood T-lymphocytes. PBMC were isolated from mild
persistent asthmatics (n = 8) before and after inhaled BUD treatment (see Materials and Methods for details). ICOS (A–B) and Foxp3 (C–D) were
assessed by flow-cytometry in CD4+CD252 and in CD4+CD25+ cells. Individual results, median and 25–75 percentiles are shown. *p,0.05. Arrows
indicate the representative dot plots.
doi:10.1371/journal.pone.0048816.g007
Immunoregulatory Effects of Budesonide
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CD25+ cells, regulating glucocorticoid-induced TNF receptor
expression [23], confers protection from TCR-mediated apoptosis
[24].
In asthma, T lymphocyte expansion, other than promoted by
increased cell survival [17], may be also promoted by other
mechanisms [25]. T lymphocytes to become fully activated require
a nonspecific co-stimulatory signal. ICOS, a co-stimulatory
molecule, is up-regulated after T lymphocyte activation and is
retained on many memory T lymphocytes. This molecule is
preferentially expressed on Th2 cells and plays an important role
in the production of IL-2, IL-4, and IL-5 from recently activated T
lymphocytes [3]. ICOS is also expressed by Tregs and exerts a
fundamental role in the generation and function of
CD4+CD25+Foxp3+ regulatory T cells [26]. ICOS-ICOS-ligand
interactions and IL-10 regulate the development and the
inhibitory function of regulatory lymphocytes [27]. Tregs with
high ICOS expression mediate stronger suppression activities [28].
In the present study, we demonstrate for the first time that
asthmatic patients show a reduced percentage of ICOS positive
cells in CD4+/CD25+ cells while they show increased percentage
of ICOS positive cells in total lymphocytes and in CD4+/CD252
cells when compared to controls. BUD reduced percentage of
ICOS positive cells in total lymphocytes and in CD4+/CD252
cells in asthmatic patients, contributing to limit the activation of
these cells. Accordingly, it has been demonstrated that dexameth-
asone reduces allostimulatory properties inhibiting the expression
of co-stimulatory molecules on dendritic cells [29]. Moreover,
prednisolone reduces the serum concentrations of a co-stimulatory
ligand, sCD86 in allergic asthma [30]. Furthermore, we show here
that BUD increases ICOS in CD4+/CD25+ further supporting
the concept that this drug is effective in controlling T lymphocyte
activation also improving the function and the activities of the
Tregs. T regulatory activities are manly related to naturally
occurring CD4+/CD25+ Tregs and to CD4+/CD252 inducible
Tregs [31]. High percentages of CD4+/CD25+ Tregs express
Foxp3, a transcription factor typically associated to T regulatory
activities [32]. This natural CD4+/CD25+ subset is thymus-born,
constitutively expresses IL-10 mRNA, does not produce IL-2 and
is resistant to apoptosis [32].
T regulatory activities have the potential to suppress pathogenic
Th2 responses thus preserving lung integrity [33] and may be
defective or overridden in patients with allergic diseases including
asthma [7]. The levels of Foxp3 mRNA in BAL from children with
asthma are lower than in healthy controls, positively correlate with
FEV1 and, after 4 weeks of treatment with inhaled corticosteroids,
significantly increase [34]. Furthermore, in severe asthmatics, the
Foxp3 protein expression in PBMC correlate with the FEV1
values and the symptom score [35].
In the present study we show that a reduced percentage of
Foxp3 positive cells was observed in CD4+/CD25+ and in CD4+/
CD252 cells from asthmatics when compared to the controls.
BUD in vitro is able to significantly increase the percentage of
Figure 8. In vivo effects of BUD in IL-10 expression in peripheral blood T-lymphocytes. PBMC were isolated from mild persistent
asthmatics (n = 8) before and after inhaled BUD treatment (see Materials and Methods for details). IL-10 expression were assessed by flow-cytometry
in CD4+CD252 (A) and in CD4+CD25+ (B) cells. Individual results, median and 25–75 percentiles are shown. *p,0.05. Arrows indicate the
representative dot plots.
doi:10.1371/journal.pone.0048816.g008
Immunoregulatory Effects of Budesonide
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Foxp3 positive cells in CD4+CD252. This is the first time that this
effect of a corticosteroid is demonstrated in the CD4+/CD252
cell population and this phenomenon may be relevant in the
control of bronchial inflammation since CD4+/CD252 T
lymphocytes ectopically expressing Foxp3 acquire the function to
control inflammation in experimentally induced inflammatory
bowel disease and to down-regulate the proliferation of CD4+/
CD252 T lymphocytes in vitro [36]. Although a previous report
in patients with systemic lupus erythematosus shows that
dexamethasone enhances Foxp3 expression without inducing a
higher antiproliferative function [37], we demonstrate here that
BUD reduced T lymphocyte proliferation upon allergen stimula-
tion in allergic asthmatics. Tregs control effector immune
responses through a diverse array of mechanisms including
secretion of the anti-inflammatory cytokines TGF and IL-10
[38]. IL-10 is essential not only for suppression of effector cells by
Treg cells but also for their differentiation [27]. IL-10, produced
by a number of different cells, affecting antigen presenting cell
function, dendritic cell maturation as well as the activation of co-
stimulatory molecules, can inhibit both Th1 and Th2 type
responses [9]. IL- 10 activates tyrosin phosphatase 1 which
dephosphorylates rapidly CD28 and ICOS co-stimulatory recep-
tors [39]. Immunosoppressive drugs induce IL-10 producing cells
from naive CD4+/CD252 cells [9] and in the present study BUD
was able to increase the expression of IL-10 in CD4+/CD25+ cells
and in CD4+/CD25+/CD127 dim T cells. The reduced
expression of CD127 distinguish cells that are activated effector
cells (that also increase CD25 and Foxp3, albeit transiently) from
genuine CD4+CD25+Foxp3+ Treg [40]. Rapid switch and
expansion of IL-10-producing cells and the use of multiple
suppressive factors represent essential mechanisms in immune
tolerance to a high dose of allergens in non-allergic individuals
[41]. In the present study inhaled BUD in patients with mild
persistent asthma is able, in vivo, to increase ICOS, Foxp3 and IL-
10 expression in CD4+/CD25+ while it decreased ICOS
expression and increased Foxp3 and IL-10 expression in CD4+/
CD252 cells. In these patients these immuno-regulatory events
promoted by BUD treatment are associated to clinical benefits
including improvements of FEV1, stability of peak flow values and
absence of symptoms. Furthermore, additional studies on
lymphocytes isolated from bronchoalveolar lavages will allow to
confirm these immuno-regulatory effects of BUD also within the
lower respiratory tract.
In conclusion, these results suggest that BUD is effective in
controlling asthma inflammation by reducing both T lymphocyte
survival and T lymphocyte co-stimulatory ICOS in CD4+/
CD252 and by increasing the survival and the activities of CD4+/
CD25+ cells. These mechanisms described in vitro are translated in
vivo and may contribute to improve asthma control. Future studies
are needed to clarify whether these immunomodulatory effects of
BUD are shared by other inhaled steroids.
Supporting Information
Figure S1 PBMC were cultured with different concen-
trations of BUD (1027, 1028 and 1029 M) and after
selecting the best concentration of BUD (1028 M) two
time points (24 and 48 hrs) were tested. Representative dot
plots were shown.
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